The SGC-Toronto collaborates widely locally and globally to supports breakthrough research in protein-focused open science tools, knowledge, and reagents to enable drug discovery. Ongoing projects involve the characterization of human and viral proteins using structural biology, biophysics and chemical biology addressing human health and diseases such as cancer, neurodegeneration, inflammation, human fertility and viral infection.  We use state-of-the-art methodologies such as semi-automated high throughput protein production and assays, and structure-guided development of novel chemical probes (tool compounds). The SGC-Toronto is developing new tools to study human health and disease with new drug modalities such as PROTACs (Targeted Protein Degradation), proximity pharmacology, the use of   artificial intelligence and machine learning and novel high throughput protein assay and screening methodologies.

The SGC-Toronto has a team of more than 50 trainees, researchers and support staff working in approximately 14,000 square feet of research space on discovery projects in the areas of chemical probes, structural biology, bioinformatics, molecular biophysics, cellular assays, and oncology target discovery. Our large wet lab is equipped with state-of-the-art infrastructure to support crystallography, protein production, protein biophysics, molecular biology, cell and tissue culture.

The SGC-Toronto laboratory, under the direction of Professor Cheryl Arrowsmith, operates within the Temerty Faculty of Medicine at the University of Toronto and is located in the MaRS Discovery District, at the heart of cosmopolitan Toronto. Scientists at the SGC-Toronto are affiliated with several University Departments including the Departments of Medical Biophysics, Pharmacology and Toxicology and Molecular Genetics.

The SGC Toronto is proud to partner with and/or host a number of international initiatives that help advance these areas of protein-based research. 

CACHE initiative

Chemical Probes Portal

Target 2035